<DOC>
	<DOCNO>NCT02014740</DOCNO>
	<brief_summary>The purpose research study learn effect Liraglutide , ( Victoza® ) , fat surround heart.Excessive amount fat around heart common people type 2 diabetes associate poor sugar control . Liraglutide injectable prescription medicine improve blood sugar control adult type 2 diabetes .</brief_summary>
	<brief_title>Effect Liraglutide Epicardial Fat Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 2 diabetes , define ADA criterion HbA1c &lt; 8 % measure least 1 month prior study BMI ≥27 kg/m2 Pretreatment Metformin Age &gt; 18 &lt; 65 year old • Known contraindication Liraglutide , previous history pancreatitis medullary thyroid carcinoma , personal family history MEN , accordance risk safety information include late updated Prescribing Information Victoza® Type 1 diabetes , define American Diabetes Association ( ADA ) criteria Insulin dependent treat type 2 diabetes Current use injectable incretins History diabetes ketoacidosis Advanced Chronic Kidney Disease , define Glomerular Filtration Rate ( GFR ) &lt; 30 mL/min/1.73m2 Clinical sign symptoms New York Heart Association ( NYHA ) class IIIIV heart failure Clinical laboratory evidence chronic active liver disease Acute chronic infective disease Cancer chemotherapy Current use systemic corticosteroid 3 month prior study Known suspect allergy Liraglutide , excipients , relate product Pregnant , breastfeed intention become pregnant Females childbearing potential use adequate contraceptive method</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Epicardial fat</keyword>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Obesity</keyword>
	<keyword>GLP-1 analog</keyword>
</DOC>